Isolated domains of type IV collagen to modify cell and tissue interactions
AssigneesYale University, University of Kansas Medical Center
InventorsMichael P. Sarras, Jr., Billy G. Hudson
Life of this patent
Estimating the term…
Abstract
The instant invention demonstrates that the 7S domain of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation affects cell division, cell differentiation, and morphogenesis.
Claims4
A method for inhibiting tumor induced angiogenesis in animal tissue comprising contacting said tissue with a polypeptide composition in an amount effective to inhibit angiogenesis, said composition comprising one or more domains of type IV collagen selected from the group consisting of NC1 domain and 7S domain.
A method for inhibiting tumor-induced angiogenesis in an animal tissue comprising contacting said tumor with a polypeptide composition comprising one or more domains of type IV collagen selected from the group consisting of NC1 domain and 7S domain.
A method for inhibiting tumor growth by inhibiting tumor-induced angiogenesis comprising contacting said tumor with a polypeptide composition comprising one or more domains of type IV collagen selected from the group consisting of NC1 domain and 7S domain.
A method for inhibiting tumor metastasis in tissue comprising contacting said tumor or tissue with a polypeptide composition comprising one or more domains of type IV collagen selected from the group consisting of NC1 domain and 7S domain.
Dependencies are inferred from the claim text.